Archives: PDF


Central Serous Chorioretinopathy: Can it be treated without Visudyne?

Given the difficulty of obtaining verteporfin for chronic CSCR, it is worth considering subthreshold laser therapy as an alternative given its comparable efficacy and practical advantages. We know that the prognosis for this disease depends on the level of disease progression, so a therapeutic option that allows for an undelayed treatment is extremely interesting.
Laser Remains an Effective Option for DME and CSCR Treatments

Laser Remains an Effective Option for DME and CSCR Treatments

Diabetic macular edema (DME) is the leading cause of irreversible visual loss in the diabetic population. Laser plays a very important role in the treatment of DME despite the use of anti-VEGF agents, said Dr. Victor Chong, consultant ophthalmic surgeon at London Medical, United Kingdom, during a symposium at the recently held APAO 2021 Virtual.

The Argument for Laser in 2021

When discussing treatment for macular pathologies like diabetic macular edema (DME) and central serous chorioretinopathy (CSCR), injection burden is a term that often appears.

Formation of the Subthreshold Ophthalmic Laser Society

Laser photocoagulation has been used in ophthalmology for many years. During photocoagulation, a continuous wave of energy is delivered to the target tissue throughout the entire duration of the laser pulse.
SubLiminal Laser Therapy for CSC

SubLiminal Laser Therapy for CSC

Central serous chorioretinopathy (CSC) is a common posterior pole disease with a high recurrence rate and etiology. Its pathogenesis is ambiguous; however, it is characterized by the decompensation of the retinal pigment epithelium (RPE) and usually results in serous detachment of neuroretina, serous pigment epithelium detachment (PED), and RPE atrophy.
Easyret treatment guidelines Subliminal

Retina Treatment: Subliminal Treatment Procedure

Retina Treatment: Subliminal Treatment Procedure by Victor CHONG, MD (UK), Royal Free London NHS Foundation Trust, Optegra Eye Hospital, Central London
Easyret treatment guidelines Multispot

Multispot Treatment Guidelines

Easyret Treatment Guidelines: Multispot mode
SubLiminal Laser for Center-Involving Diabetic Macular Edema

SubLiminal Laser for Center-Involving Diabetic Macular Edema

Diabetic retinopathy (DR) is a major microvascular complication of diabetes. It is estimated that by 2030, nearly 200 million people will be affected by this disease. During this period, visionthreatening DR will increase from 37 million to 56 million people globally. Center-involved diabetic macular edema (CI-DME) is the most common cause of decreased visual acuity in DR patients, affecting more than 750,000 patients in the United States alone.
Safe and Effective Laser Therapies: Targeting Retinal Diseases Amidst COVID-19

Safe and Effective Laser Therapies: Targeting Retinal Diseases Amidst COVID-19

In this time of uncertainty, one thing is certain (at least in ophthalmology): Retinal pathologies are not going anywhere. In fact, chronic conditions like age-related macular degeneration (AMD) and diabetic retinopathy (DR) are thought to be causing more concerns during this period of worldwide lockdown and social distancing.
An Exciting Journey in SubLiminal Laser Treatment Therapy for DME

An Exciting Journey in SubLiminal Laser Treatment Therapy for DME

DME is one of the most common causes of sightthreatening retinopathy for people with diabetes, which currently affects more than 30 million people worldwide. As the prevalence of diabetes and vision diseases related to diabetes continues to rise, so does the burden it creates on health care systems.


Quantel Medical & Ellex, 2 brands of Lumibird Medical, united with 1 objective: develop cutting-edge technologies for the diagnosis and treatment of dry eye and leading causes of blindness worldwide: glaucoma, cataracts, AMD and diabetic retinopathy.


"*" indicates required fields

The information collected through this form is recorded and transmitted to the relevant QUANTEL MEDICAL departments and enables us to send you any reply to a request via the contact form. The legal basis for the processing is consent. The data collected are kept for 3 years in digital format and are only transmitted to QUANTEL MEDICAL’s internal departments as well as to our distributors and subsidiaries. You have a right to access, rectify, contest, limit the processing of and erase data. For more information on the use of your data and your rights resulting from the amended French Data Protection Act and the GDPR, please consult our data protection policy or contact our Data Protection Officer at
Personal data compliance
For more informations on how Quantel Medical uses your data, please see our Terms and conditions.
© 2022 Quantel Medical
Share on email
Share this page by email
Share on facebook
Share this page on facebook
Share on twitter
Share this page on twitter
Share on linkedin
Share this page on linkedin